RCT: Ranolazine shows benefit for persistent angina in patients with type 2 diabetes

Source: Journal of the American College of Cardiology Area: News According to data presented at the American Society of Cardiology annual meeting, and published early online in the Journal of the American College of Cardiology, ranolazine reduced episodes of chest pain in patients with diabetes.   Researchers examined the efficacy of ranolazine versus placebo on weekly angina frequency in patients with type 2 diabetes, coronary artery disease (CAD), and chronic stable angina who remain symptomatic despite treatment with up to 2 anti-anginal agents.   The trial, Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) was a randomised, double-blind, placebo-controlled trial in which patients were randomised to twice daily placebo (n=465) or ranolazine 500mg bd (increased to 100mg bd if appropriate) for 8 weeks (n=462). Anginal episodes and nitroglycerin use were recorded with daily entry into a novel electronic diary. Primary outcome was the average weekly number of anginal episodes over the ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news

Related Links:

Conclusions: this research gives us preliminary values of the FHSQ in Spanish patients with T2DM and divided by gender, age, diabetes control, BMI, and years of diagnosis in people with T2DM.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
The healing power of ultraviolet light (UV) has flown under the radar for decades. Yet, it’s one of the most powerful detoxifying agents known to man. It kills bacteria and viruses and can be used in a clinical setting. The therapeutic benefits of light have been known for millennia. Hippocrates, the father of modern medicine, believed light was essential to balance the body and emotions. And there is good reason why, during the Spanish flu pandemic of 1918, medics discovered that severely ill patients had hugely better recovery rates when they were nursed outside and had regular exposure to sunlight.1 You see, UV r...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Health Source Type: news
The benefits of physical exercise for the prevention and management of type 2 diabetes are well established, including improved glucose control, cardiorespiratory fitness, muscular strength, muscle mass, and body composition [1]. In contrast, there is little knowledge on the specific effects of exercise training on chronic pain in this population [2]. This is despite growing evidence that people with type 2 diabetes are more likely to develop a range of rheumatological and musculoskeletal problems, and experience both widespread and neuropathic pain [3 –5].
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
TYPE 2 diabetes is a chronic condition characterised by dangerously high blood sugar levels. The condition can go undetected for years but symptoms can crop up if your blood sugar levels are consistently too high. When this happens, you may experience pain in a particular part of your body.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
AbstractFrustratingly, disease-modifying treatments for diabetic neuropathy remain elusive. Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but not in those with type 2 diabetes, which constitute the vast majority of patients. Encouragingly, recent evidence points to new metabolic risk factors and mechanisms, and thus also at novel disease-modifying strategies, which are desperately needed. Obesity has emerged as the second most important metabolic risk factor for neuropathy (diabetes being the first) from consensus findings of seven observational studies in populations across the ...
Source: Diabetologia - Category: Endocrinology Source Type: research
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
AbstractDiabetes mellitus type 2 (T2DM) is characterized by resistance of insulin receptors and/or inadequate insulin secretion resulting in metabolic and structural complications including vascular diseases, arterial hypertension and different behavioral alterations. We aimed to study the effects of the antihypertensive angiotensin AT1 receptor antagonist losartan on the T2DM-induced changes of exploratory behavior, anxiety, nociception and short term memory in normotensive Wistar and spontaneously hypertensive rats (SHRs). The experimental model of T2DM induced by a combination of high fat diet and streptozotocin, decrea...
Source: Metabolic Brain Disease - Category: Neurology Source Type: research
Publication date: Available online 4 February 2020Source: Canadian Journal of DiabetesAuthor(s): Rose Raizman, Lilach GavishAbstractDiabetic foot ulcers (DFUs) incidence is increasing with the rising global prevalence of diabetes. In spite of following best practice standard of care, most DFU are slow to heal. Photobiomodulation (PBM), previously known as low-level laser therapy, has been shown to accelerate healing of acute or chronic wounds, and specifically diabetic foot ulcers. However, the frequent applications required, translates to frequent visits at the clinic which are difficult for patients with DFU. In the foll...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
Comorbidity is the presence of one or more additional conditions co-occurring with a primary condition. In this episode, host schizophrenic Rachel Star Withers with her cohost Gabe Howard will be discussing comorbidity with schizophrenia. Comorbidity is associated with worse health outcomes, more complex clinical management and increased health care costs. Occupational therapist and host of the podcast Occupied, Brock Cook, will be joining us to discuss ways that he works with people with schizophrenia to manage multiple health issues.  Highlights from “Comorbidity with Schizophrenia” Episode [01:28] What ...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Antipsychotic Inside Schizophrenia Mental Health and Wellness Psychiatry Psychology Psychotherapy Bipolar disorder and schizophrenia comorbid comorbid psychiatric conditions Comorbidities Comorbidity Diagnosis Of Schizophrenia Livi Source Type: blogs
More News: Cardiology | Cardiovascular | Chronic Pain | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Nitroglycerin | Pain